Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 22 Aug 2025
A topical fluorescent molecular contrast agent, PARPi-FL, can detect basal cell carcinoma through intact skin in as little as five minutes in ex vivo human tissues, according to new preclinical research published in The Journal ...
Read Full NewsNeuromodulation, mind-body therapy, and other nonpharmacologic interventions are linked to improved psychiatric symptoms in people with SUD, a meta-analysis shows.
Researchers are testing CAR T-cell therapy as a way to reset the immune system in lupus, Graves’ disease and other conditions where the body’s defenses go rogue.
1.
EBCC: European Breast Cancer Conference
2.
Aster Whitefield Hospital, with 506 beds, opened.
3.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
4.
Modified personalized cancer vaccine generates powerful immune response
5.
Knowing about and avoiding bladder cancer.
1.
Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management
2.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
3.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
4.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
5.
Uncovering the Mystery of the Sessile Serrated Adenoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge